Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2006; 12(15): 2412-2416
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2412
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2412
Table 1 Characteristics of the patients
| n (%) | Mean | Median | |
| Sex | |||
| Boys | 48 (81.4) | ||
| Girls | 11 (18.6) | ||
| Age | 6-18 | 10.5 ± 3.24 | 10 |
| (yr) | |||
| Age of HBV infection | 1-14 | 3.7 ± 3.09 | 3 |
| (yr) | |||
| Duration of HBV infection | 1-16 | 6.8 ± 3.09 | 6 |
| (yr) | |||
| Completed previous IFN-α treatment | |||
| Yes | 51 (86.4) | ||
| No | 8 (13.6) | ||
| ALT activity before treatment | 20-664 | 101 ± 96.3 | 76 |
| (IU/L) | |||
| Inflammation activity score | |||
| Grade 1 | 24 (40.7) | ||
| Grade 2 | 33 (55.9) | ||
| Grade 3 | 2 (3.4) | ||
| Grade 4 | 0 | ||
| Staging | |||
| Stage 0 | 7 (11.9) | ||
| Stage 1 | 37 (62.7) | ||
| Stage 2 | 12 (20.3) | ||
| Stage 3 | 2 (3.4) | ||
| Stage 4 | 1 (1.7) | ||
| Serum HBV DNA level | 200 - 200 000 | 135 632 ± 81 018 | 200 000 |
| (copies/mL) | |||
| Lamivudnie dose (mg per kg | 1.3 - 4.1 | 3.0 ± 0.85 | 2.9 |
| of body weight) |
- Citation: Liberek A, Szaflarska-Popławska A, Korzon M, Łuczak G, Góra-Gębka M, Łoś-Rycharska E, Bako W, Czerwionka-Szaflarska M. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2412-2416
- URL: https://www.wjgnet.com/1007-9327/full/v12/i15/2412.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i15.2412